PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Stock Competitors & Peer Comparison
See PRCT's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PRCT and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PRCT | $17.25 | +0.29% | 981.9M | -8.89 | -$1.94 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $100.98 | -0.31% | 174.7B | 19.38 | $5.21 | +2.45% |
| MDT | $89.50 | +0.97% | 114.5B | 16.18 | $5.53 | +3.24% |
| SYK | $275.31 | +1.08% | 105.6B | 20.57 | $13.39 | +1.28% |
| BSX | $44.11 | +0.43% | 65.6B | 14.23 | $3.10 | N/A |
| EW | $86.83 | +0.63% | 50B | 32.16 | $2.70 | N/A |
| DXCM | $86.68 | +0.07% | 32.7B | 33.99 | $2.55 | N/A |
| GEHC | $66.78 | +0.23% | 30.2B | 14.64 | $4.56 | +0.21% |
| PHG | $25.11 | +0.60% | 24.5B | 14.35 | $1.75 | +3.97% |
Stock Comparison
Boston Scientific Corporation (NYSE: BSX-PA)
PRCT vs BSX-PA Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, PRCT's ROE is -0.31%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, PRCT is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check BSX-PA's competition here
Abbott Laboratories (NYSE: ABT)
PRCT vs ABT Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, ABT has a market cap of 174.7B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while ABT trades at $100.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas ABT's P/E ratio is 19.38. In terms of profitability, PRCT's ROE is -0.31%, compared to ABT's ROE of +0.11%. Regarding short-term risk, PRCT is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check ABT's competition here
Medtronic plc (NYSE: MDT)
PRCT vs MDT Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, MDT has a market cap of 114.5B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while MDT trades at $89.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas MDT's P/E ratio is 16.18. In terms of profitability, PRCT's ROE is -0.31%, compared to MDT's ROE of +0.11%. Regarding short-term risk, PRCT is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
PRCT vs SYK Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, SYK has a market cap of 105.6B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while SYK trades at $275.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas SYK's P/E ratio is 20.57. In terms of profitability, PRCT's ROE is -0.31%, compared to SYK's ROE of +0.16%. Regarding short-term risk, PRCT is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
PRCT vs BSX Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, BSX has a market cap of 65.6B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while BSX trades at $44.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas BSX's P/E ratio is 14.23. In terms of profitability, PRCT's ROE is -0.31%, compared to BSX's ROE of +0.15%. Regarding short-term risk, PRCT is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
PRCT vs EW Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, EW has a market cap of 50B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while EW trades at $86.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas EW's P/E ratio is 32.16. In terms of profitability, PRCT's ROE is -0.31%, compared to EW's ROE of +0.10%. Regarding short-term risk, PRCT is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
PRCT vs DXCM Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, DXCM has a market cap of 32.7B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while DXCM trades at $86.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas DXCM's P/E ratio is 33.99. In terms of profitability, PRCT's ROE is -0.31%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, PRCT is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
PRCT vs GEHC Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, GEHC has a market cap of 30.2B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while GEHC trades at $66.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas GEHC's P/E ratio is 14.64. In terms of profitability, PRCT's ROE is -0.31%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, PRCT is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
PRCT vs PHG Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, PHG has a market cap of 24.5B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while PHG trades at $25.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas PHG's P/E ratio is 14.35. In terms of profitability, PRCT's ROE is -0.31%, compared to PHG's ROE of +0.10%. Regarding short-term risk, PRCT is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
PRCT vs ZBH Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, ZBH has a market cap of 17.7B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while ZBH trades at $91.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas ZBH's P/E ratio is 10.80. In terms of profitability, PRCT's ROE is -0.31%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, PRCT is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
PRCT vs ABMD Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas ABMD's P/E ratio is 65.36. In terms of profitability, PRCT's ROE is -0.31%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, PRCT is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
PRCT vs PEN Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while PEN trades at $319.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas PEN's P/E ratio is 83.31. In terms of profitability, PRCT's ROE is -0.31%, compared to PEN's ROE of +0.11%. Regarding short-term risk, PRCT is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
PRCT vs SWAV Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas SWAV's P/E ratio is 78.76. In terms of profitability, PRCT's ROE is -0.31%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, PRCT is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
PRCT vs SNN Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, SNN has a market cap of 11.4B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while SNN trades at $27.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas SNN's P/E ratio is 18.28. In terms of profitability, PRCT's ROE is -0.31%, compared to SNN's ROE of +0.12%. Regarding short-term risk, PRCT is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check SNN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
PRCT vs BIO-B Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, BIO-B has a market cap of 10.5B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while BIO-B trades at $385.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas BIO-B's P/E ratio is -67.89. In terms of profitability, PRCT's ROE is -0.31%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, PRCT is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check BIO-B's competition here
Align Technology, Inc. (NASDAQ: ALGN)
PRCT vs ALGN Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, ALGN has a market cap of 10.4B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while ALGN trades at $145.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas ALGN's P/E ratio is 13.22. In terms of profitability, PRCT's ROE is -0.31%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, PRCT is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check ALGN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
PRCT vs BIO Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, BIO has a market cap of 10.2B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while BIO trades at $377.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas BIO's P/E ratio is 40.70. In terms of profitability, PRCT's ROE is -0.31%, compared to BIO's ROE of +0.03%. Regarding short-term risk, PRCT is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check BIO's competition here
Globus Medical, Inc. (NYSE: GMED)
PRCT vs GMED Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, GMED has a market cap of 10.1B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while GMED trades at $74.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas GMED's P/E ratio is 16.84. In terms of profitability, PRCT's ROE is -0.31%, compared to GMED's ROE of +0.12%. Regarding short-term risk, PRCT is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check GMED's competition here
Bruker Corporation (NASDAQ: BRKR)
PRCT vs BRKR Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, BRKR has a market cap of 9.6B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while BRKR trades at $63.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas BRKR's P/E ratio is 31.80. In terms of profitability, PRCT's ROE is -0.31%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, PRCT is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check BRKR's competition here
Masimo Corporation (NASDAQ: MASI)
PRCT vs MASI Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas MASI's P/E ratio is 44.43. In terms of profitability, PRCT's ROE is -0.31%, compared to MASI's ROE of +0.09%. Regarding short-term risk, PRCT is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check MASI's competition here
Glaukos Corporation (NYSE: GKOS)
PRCT vs GKOS Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, GKOS has a market cap of 9.3B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while GKOS trades at $158.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas GKOS's P/E ratio is -184.31. In terms of profitability, PRCT's ROE is -0.31%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, PRCT is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check GKOS's competition here
Bruker Corporation (NASDAQ: BRKRP)
PRCT vs BRKRP Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, BRKRP has a market cap of 9.3B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while BRKRP trades at $469.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas BRKRP's P/E ratio is 251.76. In terms of profitability, PRCT's ROE is -0.31%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, PRCT is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check BRKRP's competition here
Insulet Corp. (NASDAQ: PODD)
PRCT vs PODD Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, PODD has a market cap of 9.2B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while PODD trades at $133.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas PODD's P/E ratio is 22.68. In terms of profitability, PRCT's ROE is -0.31%, compared to PODD's ROE of +0.27%. Regarding short-term risk, PRCT is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check PODD's competition here
Haemonetics Corporation (NYSE: HAE)
PRCT vs HAE Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, HAE has a market cap of 4.8B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while HAE trades at $105.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas HAE's P/E ratio is 21.13. In terms of profitability, PRCT's ROE is -0.31%, compared to HAE's ROE of +0.11%. Regarding short-term risk, PRCT is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
PRCT vs NARI Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas NARI's P/E ratio is -59.24. In terms of profitability, PRCT's ROE is -0.31%, compared to NARI's ROE of -0.00%. Regarding short-term risk, PRCT is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
PRCT vs ITGR Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while ITGR trades at $126.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas ITGR's P/E ratio is 19.90. In terms of profitability, PRCT's ROE is -0.31%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, PRCT is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check ITGR's competition here
LivaNova PLC (NASDAQ: LIVN)
PRCT vs LIVN Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while LIVN trades at $77.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas LIVN's P/E ratio is 18.34. In terms of profitability, PRCT's ROE is -0.31%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, PRCT is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check LIVN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
PRCT vs IRTC Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, IRTC has a market cap of 3.7B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while IRTC trades at $112.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas IRTC's P/E ratio is -261.86. In terms of profitability, PRCT's ROE is -0.31%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, PRCT is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
PRCT vs AXNX Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas AXNX's P/E ratio is -709.80. In terms of profitability, PRCT's ROE is -0.31%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, PRCT is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check AXNX's competition here
Neogen Corporation (NASDAQ: NEOG)
PRCT vs NEOG Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, NEOG has a market cap of 3B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while NEOG trades at $13.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas NEOG's P/E ratio is 49.00. In terms of profitability, PRCT's ROE is -0.31%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, PRCT is more volatile compared to NEOG. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check NEOG's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
PRCT vs TMDX Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while TMDX trades at $82.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas TMDX's P/E ratio is 41.99. In terms of profitability, PRCT's ROE is -0.31%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, PRCT is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check TMDX's competition here
Butterfly Network, Inc. (NYSE: BFLY)
PRCT vs BFLY Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while BFLY trades at $9.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas BFLY's P/E ratio is -38.10. In terms of profitability, PRCT's ROE is -0.31%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, PRCT is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check BFLY's competition here
AxoGen, Inc. (NASDAQ: AXGN)
PRCT vs AXGN Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while AXGN trades at $43.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas AXGN's P/E ratio is 114.11. In terms of profitability, PRCT's ROE is -0.31%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, PRCT is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check AXGN's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
PRCT vs UFPT Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while UFPT trades at $299.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas UFPT's P/E ratio is 30.56. In terms of profitability, PRCT's ROE is -0.31%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, PRCT is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check UFPT's competition here
NuVasive, Inc. (NASDAQ: NUVA)
PRCT vs NUVA Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas NUVA's P/E ratio is 75.00. In terms of profitability, PRCT's ROE is -0.31%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, PRCT is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check NUVA's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
PRCT vs INSP Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, INSP has a market cap of 2B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while INSP trades at $70.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas INSP's P/E ratio is 30.84. In terms of profitability, PRCT's ROE is -0.31%, compared to INSP's ROE of +0.18%. Regarding short-term risk, PRCT is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check INSP's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
PRCT vs ESTA Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while ESTA trades at $65.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas ESTA's P/E ratio is -51.86. In terms of profitability, PRCT's ROE is -0.31%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, PRCT is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
PRCT vs NVCR Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while NVCR trades at $15.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas NVCR's P/E ratio is -12.18. In terms of profitability, PRCT's ROE is -0.31%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, PRCT is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check NVCR's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
PRCT vs ATEC Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while ATEC trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas ATEC's P/E ratio is -167.50. In terms of profitability, PRCT's ROE is -0.31%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, PRCT is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check ATEC's competition here
CONMED Corporation (NYSE: CNMD)
PRCT vs CNMD Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while CNMD trades at $46.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas CNMD's P/E ratio is 10.20. In terms of profitability, PRCT's ROE is -0.31%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, PRCT is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
PRCT vs HSKA Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas HSKA's P/E ratio is -62.49. In terms of profitability, PRCT's ROE is -0.31%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, PRCT is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
PRCT vs IART Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while IART trades at $16.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas IART's P/E ratio is 6.89. In terms of profitability, PRCT's ROE is -0.31%, compared to IART's ROE of -0.01%. Regarding short-term risk, PRCT is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check IART's competition here
Avanos Medical, Inc. (NYSE: AVNS)
PRCT vs AVNS Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas AVNS's P/E ratio is 27.77. In terms of profitability, PRCT's ROE is -0.31%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, PRCT is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check AVNS's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
PRCT vs TNDM Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while TNDM trades at $16.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas TNDM's P/E ratio is -17.66. In terms of profitability, PRCT's ROE is -0.31%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, PRCT is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check TNDM's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
PRCT vs SILK Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas SILK's P/E ratio is -18.96. In terms of profitability, PRCT's ROE is -0.31%, compared to SILK's ROE of -0.35%. Regarding short-term risk, PRCT is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check SILK's competition here
Artivion, Inc. (NYSE: AORT)
PRCT vs AORT Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while AORT trades at $22.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas AORT's P/E ratio is 38.23. In terms of profitability, PRCT's ROE is -0.31%, compared to AORT's ROE of -0.01%. Regarding short-term risk, PRCT is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check AORT's competition here
IRadimed Corporation (NASDAQ: IRMD)
PRCT vs IRMD Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while IRMD trades at $86.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas IRMD's P/E ratio is 43.55. In terms of profitability, PRCT's ROE is -0.31%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, PRCT is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
PRCT vs FNA Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas FNA's P/E ratio is -19.83. In terms of profitability, PRCT's ROE is -0.31%, compared to FNA's ROE of -0.35%. Regarding short-term risk, PRCT is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check FNA's competition here
Enovis Corporation (NYSE: ENOV)
PRCT vs ENOV Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, ENOV has a market cap of 1B. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while ENOV trades at $18.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas ENOV's P/E ratio is 5.20. In terms of profitability, PRCT's ROE is -0.31%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, PRCT is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check ENOV's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
PRCT vs LMRI Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, LMRI has a market cap of 974.7M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while LMRI trades at $10.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas LMRI's P/E ratio is -19.74. In terms of profitability, PRCT's ROE is -0.31%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, PRCT is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check LMRI's competition here
Bioventus Inc. (NASDAQ: BVS)
PRCT vs BVS Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, BVS has a market cap of 949.8M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while BVS trades at $14.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas BVS's P/E ratio is 18.45. In terms of profitability, PRCT's ROE is -0.31%, compared to BVS's ROE of +0.28%. Regarding short-term risk, PRCT is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
PRCT vs CBLL Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, CBLL has a market cap of 930M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while CBLL trades at $24.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas CBLL's P/E ratio is -13.93. In terms of profitability, PRCT's ROE is -0.31%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, PRCT is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check CBLL's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
PRCT vs BBNX Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, BBNX has a market cap of 923.2M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while BBNX trades at $20.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas BBNX's P/E ratio is -12.44. In terms of profitability, PRCT's ROE is -0.31%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, PRCT is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check BBNX's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
PRCT vs CSII Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas CSII's P/E ratio is -20.83. In terms of profitability, PRCT's ROE is -0.31%, compared to CSII's ROE of -0.14%. Regarding short-term risk, PRCT is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
PRCT vs SIBN Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, SIBN has a market cap of 832M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while SIBN trades at $18.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas SIBN's P/E ratio is -55.18. In terms of profitability, PRCT's ROE is -0.31%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, PRCT is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check SIBN's competition here
InMode Ltd. (NASDAQ: INMD)
PRCT vs INMD Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, INMD has a market cap of 816.5M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while INMD trades at $14.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas INMD's P/E ratio is 9.86. In terms of profitability, PRCT's ROE is -0.31%, compared to INMD's ROE of +0.12%. Regarding short-term risk, PRCT is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check INMD's competition here
Varex Imaging Corporation (NASDAQ: VREX)
PRCT vs VREX Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, VREX has a market cap of 777.2M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while VREX trades at $18.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas VREX's P/E ratio is 19.43. In terms of profitability, PRCT's ROE is -0.31%, compared to VREX's ROE of +0.05%. Regarding short-term risk, PRCT is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check VREX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
PRCT vs AHCO Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, AHCO has a market cap of 768.7M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while AHCO trades at $5.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas AHCO's P/E ratio is 11.53. In terms of profitability, PRCT's ROE is -0.31%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, PRCT is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check AHCO's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
PRCT vs AVR Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, AVR has a market cap of 752.6M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while AVR trades at $7.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas AVR's P/E ratio is -3.99. In terms of profitability, PRCT's ROE is -0.31%, compared to AVR's ROE of -0.78%. Regarding short-term risk, PRCT is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check AVR's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
PRCT vs CTKB Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, CTKB has a market cap of 741.3M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while CTKB trades at $5.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas CTKB's P/E ratio is -30.41. In terms of profitability, PRCT's ROE is -0.31%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, PRCT is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check CTKB's competition here
Surmodics, Inc. (NASDAQ: SRDX)
PRCT vs SRDX Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas SRDX's P/E ratio is -34.66. In terms of profitability, PRCT's ROE is -0.31%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, PRCT is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check SRDX's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
PRCT vs KIDS Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, KIDS has a market cap of 580M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while KIDS trades at $22.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas KIDS's P/E ratio is -19.14. In terms of profitability, PRCT's ROE is -0.31%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, PRCT is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check KIDS's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
PRCT vs APEN Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas APEN's P/E ratio is -9.43. In terms of profitability, PRCT's ROE is -0.31%, compared to APEN's ROE of -0.85%. Regarding short-term risk, PRCT is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check APEN's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
PRCT vs SSII Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, SSII has a market cap of 578.4M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while SSII trades at $2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas SSII's P/E ratio is -48.17. In terms of profitability, PRCT's ROE is -0.31%, compared to SSII's ROE of -0.27%. Regarding short-term risk, PRCT is more volatile compared to SSII. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check SSII's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
PRCT vs DCTH Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, DCTH has a market cap of 545.8M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while DCTH trades at $15.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas DCTH's P/E ratio is 1581.00. In terms of profitability, PRCT's ROE is -0.31%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, PRCT is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
PRCT vs ZIMV Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, PRCT's ROE is -0.31%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, PRCT is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check ZIMV's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
PRCT vs PACB Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, PACB has a market cap of 531.1M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while PACB trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas PACB's P/E ratio is -4.17. In terms of profitability, PRCT's ROE is -0.31%, compared to PACB's ROE of -49.62%. Regarding short-term risk, PRCT is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check PACB's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
PRCT vs TCMD Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, TCMD has a market cap of 514.7M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while TCMD trades at $22.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas TCMD's P/E ratio is 21.13. In terms of profitability, PRCT's ROE is -0.31%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, PRCT is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check TCMD's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
PRCT vs SGHT Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, SGHT has a market cap of 504.4M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while SGHT trades at $9.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas SGHT's P/E ratio is -16.55. In terms of profitability, PRCT's ROE is -0.31%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, PRCT is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check SGHT's competition here
Cerus Corporation (NASDAQ: CERS)
PRCT vs CERS Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, CERS has a market cap of 493.7M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while CERS trades at $2.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas CERS's P/E ratio is -81.40. In terms of profitability, PRCT's ROE is -0.31%, compared to CERS's ROE of -0.10%. Regarding short-term risk, PRCT is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
PRCT vs NPCE Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, NPCE has a market cap of 482.4M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while NPCE trades at $14.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas NPCE's P/E ratio is -24.82. In terms of profitability, PRCT's ROE is -0.31%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, PRCT is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check NPCE's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
PRCT vs CLPT Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, CLPT has a market cap of 459.1M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while CLPT trades at $15.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas CLPT's P/E ratio is -12.97. In terms of profitability, PRCT's ROE is -0.31%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, PRCT is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check CLPT's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
PRCT vs SENS Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, SENS has a market cap of 411.3M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while SENS trades at $9.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas SENS's P/E ratio is -4.41. In terms of profitability, PRCT's ROE is -0.31%, compared to SENS's ROE of -1.66%. Regarding short-term risk, PRCT is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
PRCT vs OFIX Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, OFIX has a market cap of 397.7M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while OFIX trades at $9.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas OFIX's P/E ratio is -6.41. In terms of profitability, PRCT's ROE is -0.31%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, PRCT is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check OFIX's competition here
CapsoVision, Inc. (NASDAQ: CV)
PRCT vs CV Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, CV has a market cap of 345.7M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while CV trades at $6.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas CV's P/E ratio is -10.98. In terms of profitability, PRCT's ROE is -0.31%, compared to CV's ROE of -1.78%. Regarding short-term risk, PRCT is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check CV's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
PRCT vs SMLR Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas SMLR's P/E ratio is 3.92. In terms of profitability, PRCT's ROE is -0.31%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, PRCT is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
PRCT vs TMCI Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, TMCI has a market cap of 290.6M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while TMCI trades at $4.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas TMCI's P/E ratio is -4.77. In terms of profitability, PRCT's ROE is -0.31%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, PRCT is more volatile compared to TMCI. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check TMCI's competition here
Avita Medical Inc. (NASDAQ: RCEL)
PRCT vs RCEL Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, RCEL has a market cap of 289.9M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while RCEL trades at $11.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas RCEL's P/E ratio is -8.10. In terms of profitability, PRCT's ROE is -0.31%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, PRCT is more volatile compared to RCEL. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check RCEL's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
PRCT vs CATX Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, CATX has a market cap of 286.3M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while CATX trades at $2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas CATX's P/E ratio is -1.89. In terms of profitability, PRCT's ROE is -0.31%, compared to CATX's ROE of -0.42%. Regarding short-term risk, PRCT is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check CATX's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
PRCT vs TLSI Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, TLSI has a market cap of 270.3M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while TLSI trades at $4.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas TLSI's P/E ratio is -2.61. In terms of profitability, PRCT's ROE is -0.31%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, PRCT is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check TLSI's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
PRCT vs INFU Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, INFU has a market cap of 259.4M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while INFU trades at $12.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas INFU's P/E ratio is 31.35. In terms of profitability, PRCT's ROE is -0.31%, compared to INFU's ROE of +0.15%. Regarding short-term risk, PRCT is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check INFU's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
PRCT vs MGRM Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas MGRM's P/E ratio is -12.00. In terms of profitability, PRCT's ROE is -0.31%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, PRCT is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
PRCT vs ELMD Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, ELMD has a market cap of 233.3M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while ELMD trades at $28.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas ELMD's P/E ratio is 21.51. In terms of profitability, PRCT's ROE is -0.31%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, PRCT is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
PRCT vs NVRO Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas NVRO's P/E ratio is -1.91. In terms of profitability, PRCT's ROE is -0.31%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, PRCT is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check NVRO's competition here
Profound Medical Corp. (NASDAQ: PROF)
PRCT vs PROF Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, PROF has a market cap of 215.1M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while PROF trades at $5.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas PROF's P/E ratio is -6.04. In terms of profitability, PRCT's ROE is -0.31%, compared to PROF's ROE of -0.56%. Regarding short-term risk, PRCT is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check PROF's competition here
RxSight, Inc. (NASDAQ: RXST)
PRCT vs RXST Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, RXST has a market cap of 193.3M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while RXST trades at $4.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas RXST's P/E ratio is -4.13. In terms of profitability, PRCT's ROE is -0.31%, compared to RXST's ROE of -0.17%. Regarding short-term risk, PRCT is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check RXST's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
PRCT vs BSGM Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas BSGM's P/E ratio is -5.81. In terms of profitability, PRCT's ROE is -0.31%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, PRCT is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check BSGM's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
PRCT vs MDGS Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas MDGS's P/E ratio is -0.27. In terms of profitability, PRCT's ROE is -0.31%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, PRCT is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check MDGS's competition here
Neuronetics, Inc. (NASDAQ: STIM)
PRCT vs STIM Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, STIM has a market cap of 177.8M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while STIM trades at $2.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas STIM's P/E ratio is -5.81. In terms of profitability, PRCT's ROE is -0.31%, compared to STIM's ROE of -1.51%. Regarding short-term risk, PRCT is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check STIM's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
PRCT vs FOCL Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, FOCL has a market cap of 169.8M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while FOCL trades at $4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas FOCL's P/E ratio is -4.38. In terms of profitability, PRCT's ROE is -0.31%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, PRCT is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check FOCL's competition here
Quanterix Corporation (NASDAQ: QTRX)
PRCT vs QTRX Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, QTRX has a market cap of 165.8M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while QTRX trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas QTRX's P/E ratio is -1.39. In terms of profitability, PRCT's ROE is -0.31%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, PRCT is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check QTRX's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
PRCT vs QIPT Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas QIPT's P/E ratio is -15.87. In terms of profitability, PRCT's ROE is -0.31%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, PRCT is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check QIPT's competition here
Quantum-Si incorporated (NASDAQ: QSI)
PRCT vs QSI Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, QSI has a market cap of 157.3M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while QSI trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas QSI's P/E ratio is -1.73. In terms of profitability, PRCT's ROE is -0.31%, compared to QSI's ROE of -0.47%. Regarding short-term risk, PRCT is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check QSI's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
PRCT vs LUCD Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, LUCD has a market cap of 153.7M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while LUCD trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas LUCD's P/E ratio is -2.18. In terms of profitability, PRCT's ROE is -0.31%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, PRCT is more volatile compared to LUCD. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check LUCD's competition here
Inogen, Inc. (NASDAQ: INGN)
PRCT vs INGN Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, INGN has a market cap of 147.3M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while INGN trades at $5.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas INGN's P/E ratio is -5.98. In terms of profitability, PRCT's ROE is -0.31%, compared to INGN's ROE of -0.13%. Regarding short-term risk, PRCT is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check INGN's competition here
iCAD, Inc. (NASDAQ: ICAD)
PRCT vs ICAD Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas ICAD's P/E ratio is -20.37. In terms of profitability, PRCT's ROE is -0.31%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, PRCT is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check ICAD's competition here
electroCore, Inc. (NASDAQ: ECOR)
PRCT vs ECOR Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, ECOR has a market cap of 99.4M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while ECOR trades at $11.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas ECOR's P/E ratio is -6.57. In terms of profitability, PRCT's ROE is -0.31%, compared to ECOR's ROE of +5.25%. Regarding short-term risk, PRCT is less volatile compared to ECOR. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check ECOR's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
PRCT vs HJLI Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas HJLI's P/E ratio is N/A. In terms of profitability, PRCT's ROE is -0.31%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, PRCT is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for PRCT.Check HJLI's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
PRCT vs ASXC Comparison September 2026
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRCT stands at 981.9M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, PRCT is priced at $17.25 on the NASDAQ, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRCT currently has a P/E ratio of -8.89, whereas ASXC's P/E ratio is -1.12. In terms of profitability, PRCT's ROE is -0.31%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, PRCT is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for PRCT.Check ASXC's competition here